Cerebrolysin® Injection is a prescription solution for injection manufactured by EVER Neuro Pharma. Each mL contains 215.2 mg of Cerebrolysin concentrate in aqueous solution. In countries where the product is authorized, local prescribing information lists uses relating to cerebrovascular and neurological disorders, including stroke, certain dementias and traumatic brain injury. Approved indications and availability vary by country.
Product details are based on the official Cerebrolysin prescribing information. The listed container sizes are not necessarily marketed in every country.
Cerebrolysin is a complex mixture of low-molecular-weight peptides and amino acids derived from porcine brain tissue. It is used in some countries in selected neurological and cerebrovascular settings. Evidence differs by condition, and its use should not be presented as a proven cure or a replacement for established stroke, dementia or traumatic brain injury care.
Commercial searches commonly include Cerebrolysin Injection, Cerebrolysin 215.2 mg/mL, Cerebrolysin 10 mL, Cerebrolysin Ampoules, Cerebrolysin Injection Price, Cerebrolysin Composition and Cerebrolysin EVER Pharma.
Check the precise container size, product labeling, supplier authorization and destination-country requirements before purchase. The official manufacturer states that Cerebrolysin is not registered with the U.S. FDA and is not approved for sale or distribution in the United States.
What is Cerebrolysin Injection?
Cerebrolysin is a branded porcine brain-derived peptide and amino-acid preparation supplied as a solution for injection.
What is the concentration of Cerebrolysin?
The referenced Austrian prescribing information states that each mL contains 215.2 mg of Cerebrolysin concentrate. This should not be interpreted as the concentration of one individually identified active peptide.
What sizes are available?
The available ampoule or vial sizes depend on the national product presentation. The Austrian product information documents several sizes, including 1 mL, 2 mL, 5 mL and 10 mL ampoules, as well as larger containers.
Is Cerebrolysin FDA-approved?
No. The official manufacturer states that Cerebrolysin is not registered with the U.S. FDA and is not approved for sale or distribution in the United States. Regulatory status must be verified separately for other markets.
Is Cerebrolysin a generic medicine?
Cerebrolysin® is a branded preparation. It should not automatically be described as a conventional generic, and similarity to another peptide preparation does not establish equivalence.
Is Cerebrolysin proven to improve recovery after stroke or dementia?
The evidence is condition-specific and not definitive. A Cochrane review of acute ischaemic stroke found no likely reduction in all-cause mortality and reported a possible increase in non-fatal serious adverse events. The Cochrane review of vascular dementia also judged the supporting evidence to be weak. These limitations should be considered alongside the applicable local prescribing information.
Medical Disclaimer: This information is for educational purposes only and does not replace professional medical advice or official prescribing information. Cerebrolysin should only be used under appropriate medical supervision where authorized.
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.